Merck and Moderna Stock Prices Soar Following Promising Melanoma Vaccine Trial Results

Money 5 sources 11 articles
Broke: Updated:
Merck and Moderna Stock Prices Soar Following Promising Melanoma Vaccine Trial Results
Photo: MarketWatch
money· A press review of 5 outlets

  1. Merck, Moderna Stocks Soar After Melanoma Trial Success Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)

    Compare 4 other versions
    ZeroHedge

    Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company.

    MarketWatch

    Moderna and Merck’s first-of-its-kind cancer vaccine helped people with melanoma live longer in a late-stage trial, and shares of both companies are soaring.

    Financial Times

    Moderna share price doubles on melanoma vaccine trial success Company’s melanoma cancer vaccine being developed with Merck

    CNBC

    An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.

  2. The vaccine candidate is a combination of an mRNA therapy and the cancer drug Keytruda

    Compare 1 other version
    CNBC

    The mRNA-based shot in combination with Merck's immunotherapy Keytruda met key goals in the phase three trial in more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery.

  3. Today's results represent a landmark moment for adjuvant melanoma treatment.This is the first Phase 3 study to show that intismeran,a treatment designed based on the unique mutational 'fingerprint' of a patient's own tumor, given in combination with pembrolizumab, can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared with KEYTRUDA alone.

    Compare 2 other versions
    CNBC

    The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone. The treatment also reduced the risk of the cancer spreading to distant parts of the body. Those results build on positive phase two trial data on the same regimen earlier this year.

    MarketWatch

    The vaccine, intismeran autogene, is an mRNA-based therapy that is paired with Merck’s Keytruda, one of the world’s top-selling cancer drugs. It’s the first Phase 3 data for the closely watched experimental cancer vaccine.

  4. As of 0700 ET, Moderna shares were up 60% and trading around $100 per share. Short interest represents 13.5% of the float, equivalent to 49.8 million shares. Merck shares are up 7% in premarket as well.

    Compare 1 other version
    CNBC

    Merck shares climbed more than 1% in premarket trading, while Moderna's stock jumped more than 10%.

From the margins

4 details only one outlet reported

Independent claims that didn't surface elsewhere in our corpus. Treat as supplementary — not corroborated across outlets.

  1. 01 Bloomberg

    Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss A record surge in Moderna Inc.’s shares delivered a $5 billion blow to short sellers who had bet that the vaccine maker’s years-long slump would continue.

  2. 02 CNBC

    My top 10 things to watch Wednesday, Aug. 19 1. Futures are jumping after the Treasury Department said this morning it will more than double the size of its government debt purchases . Bond yields had been spiraling in recent weeks. This is an obvious Trump administration "put." The administration wants the stock market rally preserved in the worst way, and some might say they're doing it in the worst way. 2. Moderna is surging over 90% this morning after the company's experimental cancer vaccine, jointly developed with Merck , showed promise in a late-stage trial focused on melanoma. Cracked the holy grail. While there's heavy short interest in Moderna, this vaccine is one reason why I said last month the stock was finally investable again. Merck shares are up almost 7%.

  3. 03 ZeroHedge

    Professor Georgina Long, the study's principal investigator, medical director of Melanoma Institute Australia, and chair of Melanoma Medical Oncology and Translational Research at the University of Sydney, wrote in a statement:

  4. 04 Financial Times

    Moderna’s cancer shot: exciting for investors, inconclusive for patients A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns

Assembled from 4 corroborated claims drawn from 5 independent outlets. Every passage above is taken verbatim — Dorothy doesn't paraphrase or summarize.

Fact Corroboration

Which sources independently confirm the same facts. Hover a claim to see its sources, or a source to see what it corroborates.

Coverage by Perspective

Center
10
Lean-Right
1

Source Similarity

Connections show how similarly each outlet covered this story. Thicker lines = more similar framing.

Sources (5)

  • ft
  • cnbc
  • marketwatch
  • bloomberg
  • zerohedge

Original Articles (11)

Center Moderna, Merck Revive mRNA Hopes With Melanoma Success — Bloomberg
Center Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss — Bloomberg
Center Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers — Bloomberg
Center Merck, Moderna Stocks Soar After Melanoma Trial Success — Bloomberg
Center Merck, Moderna Melanoma Vaccine Study Succeeds — Bloomberg
Center Moderna’s stock doubles on promising cancer-vaccine results — MarketWatch
Center Jim Cramer's top 10 things to watch in the stock market Wednesday — CNBC
Center Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial — CNBC
Lean Right Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success — ZeroHedge
Center Moderna’s cancer shot: exciting for investors, inconclusive for patients — Financial Times
Center Moderna share price doubles on melanoma vaccine trial success — Financial Times